GSK Australia has announced that its TrelegyEllipta (fluticasone furoate, umeclidinium and vilanterol) has been PBS approved for the long term, once-daily maintenance treatment of appropriate adult patients with moderate to severe chronic obstructive pulmonary disease.
The product is a combination of three molecules in an Ellipta dry powder inhaler that only needs to be taken in a single inhalation, once a day - visit au.gsk.com for full PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 May 18
